⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
ATYR News
aTyr Pharma, Inc. Common Stock
aTyr Pharma Provides Update on Timing of Regulatory Response for Planned Phase 3 Study of Efzofitimod in Pulmonary Sarcoidosis
globenewswire.com
ATYR
Form 8-K
sec.gov
ATYR
aTyr Pharma Announces Second Quarter 2026 Results, Program Prioritization and Corporate Restructuring to Support Efzofitimod Program in ILD
globenewswire.com
ATYR
Form 8-K
sec.gov
ATYR
aTyr Pharma to Present Subgroup Analysis of Phase 3 EFZO-FIT™ Study of Efzofitimod in Pulmonary Sarcoidosis at WASOG 2026
globenewswire.com
ATYR
Form 8-K
sec.gov
ATYR
Form 8-K
sec.gov
ATYR
Sensorion Appoints Fred Chereau as Chief Executive Officer
businesswire.com
ATYR
Form 8-K
sec.gov
ATYR
aTyr Pharma Announces First Quarter 2026 Results and Provides Corporate Update
globenewswire.com
ATYR